Publication:
Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study

Simple item page
dc.contributor.authorRojo Todo, F.
dc.contributor.authorStradella, A.
dc.contributor.authorGarcía Sáenz, J. A.
dc.contributor.authorBermejo de las Heras, B.
dc.contributor.authorAlonso Romero, José Luis
dc.contributor.authorBarnadas, A.
dc.contributor.authorIzarzugaza Peron, Y.
dc.contributor.authorAlba, E.
dc.contributor.authorLópez Tarruella, S.
dc.contributor.authorHenao Carrasco, F.
dc.contributor.authorCarrasco, E.
dc.contributor.authorCaballero, R.
dc.contributor.authorDel Campo, M.
dc.contributor.departmentMedicina
dc.date.accessioned2024-11-05T11:37:46Z
dc.date.available2024-11-05T11:37:46Z
dc.date.issued2020-09
dc.description© 2020 European Society for Medical Oncology. This document is the Published version of a Published Work that appeared in final form in Annals of Oncology. To access the final edited and published work see https://doi.org/10.1016/j.annonc.2020.08.456
dc.description.abstractT-DM1 is the standard second-line treatment for HER2-positive Metastatic Breast Cancer (HER2+ MBC) patients. In clinical practice, it is not possible to predict which patients will benefit the most from T-DM1. Furthermore, the mechanisms of primary and acquired resistance to T-DM1 remain largely uncharacterized. The task of uncovering such mechanisms in a clinical setting is challenging and requires a comprehensive approach.es
dc.formatapplication/pdfes
dc.format.extent1es
dc.identifier.citationAnnals of Oncology, 2020, Vol. 31, Issued S4, pp. S391
dc.identifier.doihttps://doi.org/10.1016/j.annonc.2020.08.456
dc.identifier.issnPrint: 0923-7534
dc.identifier.issnElectronic: 1569-8041
dc.identifier.urihttp://hdl.handle.net/10201/146001
dc.languageenges
dc.publisherElsevier
dc.relationRochees
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0923753420404521?via%3Dihub
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.titleUnraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA studyes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS0923753420404521.pdf
Size:
85.62 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos